Gut microbiota therapy in gastrointestinal diseases

The human gut microbiota, consisting of trillions of microorganisms, plays a crucial role in gastrointestinal (GI) health and disease. Dysbiosis, an imbalance in microbial composition, has been linked to a range of GI disorders, including inflammatory bowel disease (IBD), irritable bowel syndrome (I...

Full description

Saved in:
Bibliographic Details
Main Authors: Hanif Ullah, Safia Arbab, Chengting Chang, Saira Bibi, Nehaz Muhammad, Sajid Ur Rehman, Suleman, Irfan Ullah, Inam Ul Hassan, Yali Tian, Ka Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Cell and Developmental Biology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fcell.2025.1514636/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849722289156784128
author Hanif Ullah
Safia Arbab
Chengting Chang
Saira Bibi
Nehaz Muhammad
Sajid Ur Rehman
Suleman
Suleman
Irfan Ullah
Inam Ul Hassan
Yali Tian
Ka Li
author_facet Hanif Ullah
Safia Arbab
Chengting Chang
Saira Bibi
Nehaz Muhammad
Sajid Ur Rehman
Suleman
Suleman
Irfan Ullah
Inam Ul Hassan
Yali Tian
Ka Li
author_sort Hanif Ullah
collection DOAJ
description The human gut microbiota, consisting of trillions of microorganisms, plays a crucial role in gastrointestinal (GI) health and disease. Dysbiosis, an imbalance in microbial composition, has been linked to a range of GI disorders, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, and colorectal cancer. These conditions are influenced by the interactions between the gut microbiota, the host immune system, and the gut-brain axis. Recent research has highlighted the potential for microbiome-based therapeutic strategies, such as probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary modifications, to restore microbial balance and alleviate disease symptoms. This review examines the role of gut microbiota in the pathogenesis of common gastrointestinal diseases and explores emerging therapeutic approaches aimed at modulating the microbiome. We discuss the scientific foundations of these interventions, their clinical effectiveness, and the challenges in their implementation. The review underscores the therapeutic potential of microbiome-targeted treatments as a novel approach to managing GI disorders, offering personalized and alternative options to conventional therapies. As research in this field continues to evolve, microbiome-based interventions hold promise for improving the treatment and prevention of gastrointestinal diseases.
format Article
id doaj-art-3df51627e9a34e63b959d3d2c4b708dc
institution DOAJ
issn 2296-634X
language English
publishDate 2025-02-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cell and Developmental Biology
spelling doaj-art-3df51627e9a34e63b959d3d2c4b708dc2025-08-20T03:11:22ZengFrontiers Media S.A.Frontiers in Cell and Developmental Biology2296-634X2025-02-011310.3389/fcell.2025.15146361514636Gut microbiota therapy in gastrointestinal diseasesHanif Ullah0Safia Arbab1Chengting Chang2Saira Bibi3Nehaz Muhammad4Sajid Ur Rehman5 Suleman6 Suleman7Irfan Ullah8Inam Ul Hassan9Yali Tian10Ka Li11Medicine and Engineering Interdisciplinary Research Laboratory of Nursing & Materials, Nursing Key Laboratory of Sichuan Province, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan, ChinaLanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, ChinaMedicine and Engineering Interdisciplinary Research Laboratory of Nursing & Materials, Nursing Key Laboratory of Sichuan Province, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan, ChinaDepartment of Zoology Hazara University Manshera, Dhodial, PakistanHebei Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology, Hebei Collaborative Innovation Center for Eco-Environment, College of Life Sciences, Hebei Normal University, Shijiazhuang, Hebei, ChinaSchool of Public Health and Emergency Management, School of Medicine, Southern University of Science and Technology, Shenzhen, ChinaDepartment of Zoology, Government Post Graduate Collage, Swabi, PakistanHigher Education Department, Civil Secretariat Peshawar, Peshawar, PakistanDepartment of Biotechnology and Genetics Engineering, Hazara University, Manshera, PakistanDepartment of Microbiology, Hazara University Manshera, Manshera, PakistanMedicine and Engineering Interdisciplinary Research Laboratory of Nursing & Materials, Nursing Key Laboratory of Sichuan Province, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan, ChinaMedicine and Engineering Interdisciplinary Research Laboratory of Nursing & Materials, Nursing Key Laboratory of Sichuan Province, West China Hospital, West China School of Nursing, Sichuan University, Chengdu, Sichuan, ChinaThe human gut microbiota, consisting of trillions of microorganisms, plays a crucial role in gastrointestinal (GI) health and disease. Dysbiosis, an imbalance in microbial composition, has been linked to a range of GI disorders, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, and colorectal cancer. These conditions are influenced by the interactions between the gut microbiota, the host immune system, and the gut-brain axis. Recent research has highlighted the potential for microbiome-based therapeutic strategies, such as probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary modifications, to restore microbial balance and alleviate disease symptoms. This review examines the role of gut microbiota in the pathogenesis of common gastrointestinal diseases and explores emerging therapeutic approaches aimed at modulating the microbiome. We discuss the scientific foundations of these interventions, their clinical effectiveness, and the challenges in their implementation. The review underscores the therapeutic potential of microbiome-targeted treatments as a novel approach to managing GI disorders, offering personalized and alternative options to conventional therapies. As research in this field continues to evolve, microbiome-based interventions hold promise for improving the treatment and prevention of gastrointestinal diseases.https://www.frontiersin.org/articles/10.3389/fcell.2025.1514636/fullgut microbiotagastrointestinal diseasescancertherapydysbiosis
spellingShingle Hanif Ullah
Safia Arbab
Chengting Chang
Saira Bibi
Nehaz Muhammad
Sajid Ur Rehman
Suleman
Suleman
Irfan Ullah
Inam Ul Hassan
Yali Tian
Ka Li
Gut microbiota therapy in gastrointestinal diseases
Frontiers in Cell and Developmental Biology
gut microbiota
gastrointestinal diseases
cancer
therapy
dysbiosis
title Gut microbiota therapy in gastrointestinal diseases
title_full Gut microbiota therapy in gastrointestinal diseases
title_fullStr Gut microbiota therapy in gastrointestinal diseases
title_full_unstemmed Gut microbiota therapy in gastrointestinal diseases
title_short Gut microbiota therapy in gastrointestinal diseases
title_sort gut microbiota therapy in gastrointestinal diseases
topic gut microbiota
gastrointestinal diseases
cancer
therapy
dysbiosis
url https://www.frontiersin.org/articles/10.3389/fcell.2025.1514636/full
work_keys_str_mv AT hanifullah gutmicrobiotatherapyingastrointestinaldiseases
AT safiaarbab gutmicrobiotatherapyingastrointestinaldiseases
AT chengtingchang gutmicrobiotatherapyingastrointestinaldiseases
AT sairabibi gutmicrobiotatherapyingastrointestinaldiseases
AT nehazmuhammad gutmicrobiotatherapyingastrointestinaldiseases
AT sajidurrehman gutmicrobiotatherapyingastrointestinaldiseases
AT suleman gutmicrobiotatherapyingastrointestinaldiseases
AT suleman gutmicrobiotatherapyingastrointestinaldiseases
AT irfanullah gutmicrobiotatherapyingastrointestinaldiseases
AT inamulhassan gutmicrobiotatherapyingastrointestinaldiseases
AT yalitian gutmicrobiotatherapyingastrointestinaldiseases
AT kali gutmicrobiotatherapyingastrointestinaldiseases